Veterinarian training courses library : Dog / Dermatology

  • DV Diana FERREIRA
    Dipl. ECVD
    Video time : 32 min + MCQ
    Dermatology
    Teaching goals
    • Scaling is an accumulation of loose debris from the stratum corneum (corneocytes). Scaling can have various appearances and be dry, thin, slab or greasy and vary in color from white, silver, yellow, brown or grey.
    • Corneocytes are the end product of epidermal keratinization and the normal loss of these cells is not visible to the naked eye as corneocytes are released individually or in small groups. In abnormal scaling, there is a loss of large scales. Scaling may be primary in primary idiopathic seborrhea and ichthyosis. However, scaling is more often secondary to a chronic inflammatory process. In the presence of pruritus, the differential diagnosis should include parasitic infections, allergies, infectious diseases such as pyoderma or Malassezia dermatitis.
    • If pruritus is not present, differential diagnoses should include primary endocrinopathies, demodicosis, dermatophytosis, leishmaniasis, nutritional imbalances, metabolic diseases, and cutaneous neoplasia such as cutaneous epitheliotropic lymphoma. In cats, exfoliative dermatitis associated or not with thymoma should also be considered.
    DV Diana FERREIRA
    Dipl. ECVD
    Video time : 28 min + MCQ
    Dermatology
    Teaching goals
    • LED is a relatively benign, autoimmune condition that affects the dog's nasal planum and in which systemic manifestations are absent.
    • It is the second most common immune-mediated skin pathology in dogs.
    • Exposure to ultraviolet light aggravates and exacerbates LED and there are breeds that may be predisposed since they are reported more frequently, as the Collie, Shetland Sheep Dog, Australian Shepherd, German Shepherd and Siberian Husky.
    • Therapeutic approaches are multiple and different effectiveness has been reported.
    DV Diana FERREIRA
    Dipl. ECVD
    Video time : 34 min + MCQ
    Dermatology
    Teaching goals
    • In recent years, new therapeutic options have been developed for the management of CAD, and, in parallel with the evolution in the knowledge of the pathophysiology of this condition, a new way of looking at the manner we use these new therapies has also emerged.
    • Currently, a proactive therapeutic approach is emphasized in which, while correcting the underlying pathogenesis whenever possible, active relapses are actively prevented, through a constant control of the inflammation associated with the allergic condition.
    • In this new therapeutic approach, the management of CAD is done in two phases:
    • A first phase of REACTIVE therapy, in which the active clinical signs (pruritic and lesional being acute or chronic) is rapidly controlled in order to induce clinical remission;
    • A second phase of PROACTIVE therapy with the goal of preventing relapses, through the regular control of subclinical inflammation.